Cargando…
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover characteristics that predict pembrolizumab respo...
Autores principales: | Su, Tianying, Duran, George E., Kwang, Alexa C., Ramchurren, Nirasha, Fling, Steven P., Kim, Youn H., Khodadoust, Michael S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423847/ https://www.ncbi.nlm.nih.gov/pubmed/36046812 http://dx.doi.org/10.1080/2162402X.2022.2115197 |
Ejemplares similares
-
Pembrolizumab-associated tumor development in a patient with Sézary syndrome
por: Malachowski, Stephen J., et al.
Publicado: (2019) -
New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
por: Greene, Evan, et al.
Publicado: (2021) -
Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome
por: Fong, Sophia, et al.
Publicado: (2020) -
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
por: Phillips, Darci, et al.
Publicado: (2021) -
Targeted killing of TNFR2-expressing tumor cells and T(regs) by TNFR2 antagonistic antibodies in advanced Sézary syndrome
por: Torrey, H, et al.
Publicado: (2018)